Received Sep 12, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MNQ | MENINGOCOCCAL CONJUGATE (MENVEO) | NOVARTIS VACCINES AND DIAGNOSTICS | 2 | Z92L4 | — |
Second dose was administered on August 12th, 2025; This non-serious case was reported by a other health professional via call center representative and described the occurrence of extra dose administered in a 12-year-old female patient who received Men ACWY-CRM NVS (Menveo) (batch number Z92L4, expiry date 31-JAN-2026) for prophylaxis. Previously administered products included Menveo (received first dose on 07-AUG-2024 of batch number NG9E2 and expiry date of 30-JUN-2025). On 12-AUG-2025, the patient received the 2nd dose of Menveo. On 12-AUG-2025, an unknown time after receiving Menveo, the patient experienced extra dose administered (Verbatim: Second dose was administered on August 12th, 2025). The outcome of the extra dose administered was not applicable. Additional Information: GSK Receipt Date: 14-AUG-2025 Practice manager needs to ask that it looks like they had given a Menveo. They had given it to a patient too early, the second dose and so, the reporter asked that need to give the information and could respond with any contraindications that the reporter need to document. Both doses were Menveo 1-vial presentation.